SITC 2025 Science Coverage – Nov. 9

By Keegan Mager posted 24 days ago
Preclinical development of macrophage-targeting CAR monocytes to improve immunotherapy outcomes in breast cancer 254. Targeting tumor-associated macrophages with CAR-monocytes as a first-in-class approach for cellular therapy in breast cancer Daniel Michaud (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States) presented a first-in-class platform of using CAR-monocytes to limit tumor-associated macrophage (TAMs) function in breast cancer tumors. TAMs have been well-characterized as inhibitory hurdles for T cell function in solid tumors. TAM-targeting CAR T cells showed some anti-cancer activity in mouse models ...
0 comments

SITC 2025 Science Coverage – Nov. 8

By Keegan Mager posted 25 days ago
Development of QVT Score, a novel radiomic predictive biomarker of immunotherapy response and early survival outcomes in non-small cell lung cancer 66. QVT Score, a radiomic biomarker of tumor vascularity, enables immune checkpoint inhibitor (ICI) outcome prediction and early survival assessment in NSCLC Young Kwang Chae (Northwestern University, Chicago, IL, United States) presented the development of QVT Score, a novel radiomic biomarker of tumor vascularity, to predict immunotherapy response and survival outcomes in non-small cell lung cancer (NSCLC). This work builds upon previous studies of the relationship between tumor angiogenesis ...
0 comments

SITC 2025 Science Coverage – Nov. 7

By Keegan Mager posted 26 days ago
Overall survival analysis of HARMONi-A: PD-1 x VEGF bispecific antibody ivonescimab with chemotherapy for non-small cell lung cancer 1348. Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment Xiuning Le (The University of Texas MD Anderson Cancer Center, Houston, TX, United States) presented the final and only overall survival (OS) analysis of HARMONi-A study investigating ivonescimab with chemotherapy versus chemotherapy in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) ...
0 comments

2025 ESMO Congress Correspondent Notes

By Thomas Martin posted 10-21-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ESMO Annual Meeting on Oct. 19 and 20, 2025. 2025 Scientific Highlights Bexmarilimab, a macrophage reprogramming monoclonal antibody, in combination with azacitidine for high-risk myelodysplastic syndrome 1249MO. Macrophage reprogrammer bexmarilimab plus azacitidine in myelodysplastic syndrome: PK/PD and biomarker results from the phase I/II BEXMAB study Mika Kontro (University of Helsinki, Helsinki, Finland) reported safety and efficacy data from the phase 1/2 BEXMAB study ...
0 comments

2025 ESMO Congress Correspondent Notes

By Thomas Martin posted 10-20-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ESMO Annual Meeting on Oct. 17 and 18, 2025. 2025 Scientific Highlights Efficacy and safety of mRNA-4359, an mRNA cancer vaccine targeting PD-L1 and IDO1, in combination with pembrolizumab for immune checkpoint inhibitor resistant/refractory melanoma 1515MO. Clinical outcomes and PD-L1 expression analyses from a trial of mRNA-4359 plus pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma David J. Pinato (Imperial College London Hammersmith Hospital, ...
0 comments

Highlights from ASCO June 3, 2025

By Thomas Martin posted 06-04-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on June 3, 2025. 2025 Scientific Highlights Subgroup analyses of COMPASSION-16: Bispecific PD-1 x CTLA-4 antibody cadonilimab plus chemotherapy with or without bevacizumab for first-line persistent, recurrent, or metastatic cervical cancer 5509. Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16. Xiaohua Wu (Fudan University Shanghai Cancer Center, Shanghai, ...
0 comments

Highlights from ASCO June 2, 2025

By Thomas Martin posted 06-03-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on June 2, 2025. 2025 Scientific Highlights Dose finding and dose expansion reports of LINKER-MM2, linvoseltiamab, a BCMAxCD3 bispecific antibody, in combination with protease inhibitor bortezomib for patients with heavily pretreated multiple myeloma 7510. Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial. Xavier Leleu (Hospital La Mileterie, Poitiers, ...
0 comments

Highlights from ASCO May 31, 2025

By Thomas Martin posted 06-01-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on May 31, 2025. 2025 Scientific Highlights Adjuvant cemiplmab prevents recurrence of cutaneous squamous cell carcinoma in patients at high risk of disease recurrence 6001. Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). Danny Rischin (Peter MacCallum Cancer Centre, Melbourne, VIC, Australia) presented the primary analysis of the phase 3 C-POST study comparing the efficacy and ...
0 comments

Highlights from ASCO May 30, 2025

By Thomas Martin posted 05-31-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ASCO Annual Meeting on May 30, 2025. 2025 Scientific Highlights Continued clinical benefits of nivolumab and ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer 3501. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW. Heniz-Josef Lenz (University ...
0 comments

2025 AACR Annual Meeting (April 25–30, 2025)

By Thomas Martin posted 05-01-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 AACR Annual Meeting. 2025 Scientific Highlights Addition of perioperative pembrolizumab to the standard of care significantly improves event free survival in patients with head and neck squamous cell carcinoma CT001. Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study Ravindra Uppaluri (Brigham and Women's Hospital and Harvard Medical School/Dana-Farber ...
0 comments

ESMO Immuno-Oncology Congress 2024 (Dec. 11-13)

By Thomas Martin posted 12-16-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Immuno-Oncology Congress 2024 . Below is a recap of highlighted research presented from Dec. 11 –13, 2024. 2024 Scientific Highlights Wednesday, Dec. 11, 2024 Gut microbiota diversity and composition in patients enrolled in the JCOG2007 trial reveal associations with efficacy outcomes and toxicity to chemo-immunotherapy 1O - Exploration of Gut Microbiota Biomarkers in Treatment-Naïve Advanced NSCLC Patients Undergoing Chemo-Immunotherapy: ...
0 comments

ASH Annual Meeting 2024 (Dec. 7–9)

By Thomas Martin posted 12-11-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASH Annual Meeting 2024. Below is a recap of highlighted research presented from Dec. 7 –9, 2024. 2024 Scientific Highlights Safety and efficacy of Meta10-19, an IL-10 expressing CD19 CAR T-cell therapy for relapsed or refractory B-cell malignancies 92. IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies Yongxian Hu (Zhejiang University School of Medicine, Zhejiang University, ...
0 comments

SITC 2024 Science Coverage – Nov. 10

By Keegan Mager posted 11-11-2024
Artificial intelligence- and machine learning-based approaches to identify biomarkers of patient response to immunotherapy for non-small cell lung cancer 77. Predicting the tumor microenvironment molecular composition to assess immunotherapy efficacy in non-small cell lung cancer from digital histopathology images Alex Chen (National Cancer Institute, Bethesda, MD, USA) described a novel artificial intelligence- (AI-) based approach to characterize the composition of the tumor microenvironment (TME) using histopathology images of samples from patients with non-small cell lung cancer (NSCLC) and how to use this characterization as a predictive ...
0 comments

SITC 2024 Science Coverage – Nov. 9

By Keegan Mager posted 11-10-2024
Safety and clinical activity of invikafusp alfa, a selective T cell activator, against antigen-rich solid tumors 1470. START001: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1 James Gulley (National Cancer Institute, Bethesda, MD, USA) presented results from the STARt-001 trial, phase 1/2 study investigating invikafusp alfa, a dual T cell agonist for the treatment of anti-PD(L)1-resistant, antigen-rich solid tumors. Invikafusp alfa is a selective T cell activator consisting of a selective Vβ T ...
0 comments

SITC 2024 Science Coverage – Nov. 8

By Keegan Mager posted 11-09-2024
Targeting the telomeres of non-small cell lung cancer cells to overcome resistance to immune checkpoint inhibitors 1492. Telomere-targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation - A phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients. Victor Zaporojan (MAIA Biotechnology, Inc., Chicago, IL, USA) presented an ongoing phase 2 study investigating 6-thio-2’-deoxyguanosine (6-thio-dG; THIO), a first-in-class small molecule targeting telomerase positive (TERT+) cancer cells, in combination with cemiplimab for patients with advanced non-small cell lung cancer ...
0 comments

ESMO Congress 2024 - Sept. 15 and Sept. 16

By Thomas Martin posted 09-16-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Congress 2024. Below is a recap of highlighted research presented on Sunday, Sept. 15, 2024 and Monday, Sept.16, 2024. 2024 Scientific Highlights Post-hoc analysis of pre-treatment samples from CheckMate 9ER to identify serum glycoproteomic predictive and prognostic biomarkers for advanced renal cell carcinoma 1694MO. Novel serum glycoproteomic biomarkers predict response to Nivolumab plus Cabozantinib (NIVO+CABO) versus Sunitinib (SUN) in advanced RCC (aRCC): analysis from CheckMate ...
0 comments

ESMO Congress 2024 - Sept. 13 and 14

By Thomas Martin posted 09-16-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Congress 2024. Below is a recap of highlighted research presented from Friday, Sept. 13, 2024 and Saturday, Sept. 14, 2024. 2024 Scientific Highlights Comparing overall survival associated with BCMA-targeting CAR T cell therapies vs. bispecific antibodies for multiple myeloma 802MO. Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma Junmin Song (Albert Einstein College of Medicine, Bronx, NY, United States of America) ...
0 comments

ASCO 2024 Annual Meeting (June 4)

By Thomas Martin posted 06-05-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Tuesday, June 4, 2024. 2024 Scientific Highlights Safety and efficacy of immune checkpoint inhibitor atezolizumab in patients with advanced solid tumors with high tumor mutation burden LBA2509. Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. Rafal Dziadziuszko (Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical ...
0 comments

ASCO 2024 Annual Meeting (June 3)

By Thomas Martin posted 06-04-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Monday, June 3, 2024. 2024 Scientific Highlights Combination therapy with lenvatinib and pembrolizumab is associated with clinical benefits for advanced renal cell carcinoma across a variety of biomarker subtypes 4504. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. Toni K. Choueiri (Dana Farber Cancer Institute, Boston, MA) reported biomarker analyses ...
0 comments

ASCO 2024 Annual Meeting (June 2)

By Thomas Martin posted 06-03-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Sunday, June 2, 2024. 2024 Scientific Highlights Blockade of TIGIT improves the anti-tumor efficacy of pembrolizumab for previously treated advanced mismatch repair-deficient endometrial cancer 5502. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. Carlos ...
0 comments